Allogene Therapeutics (ALLO) Operating Expenses (2019 - 2025)
Historic Operating Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $44.9 million.
- Allogene Therapeutics' Operating Expenses fell 3744.11% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.4 million, marking a year-over-year decrease of 2365.53%. This contributed to the annual value of $273.2 million for FY2024, which is 1665.82% down from last year.
- Per Allogene Therapeutics' latest filing, its Operating Expenses stood at $44.9 million for Q3 2025, which was down 3744.11% from $56.8 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Operating Expenses registered a high of $99.1 million during Q1 2023, and its lowest value of $44.9 million during Q3 2025.
- In the last 5 years, Allogene Therapeutics' Operating Expenses had a median value of $71.8 million in 2024 and averaged $73.6 million.
- As far as peak fluctuations go, Allogene Therapeutics' Operating Expenses surged by 3039.73% in 2022, and later plummeted by 3744.11% in 2025.
- Quarter analysis of 5 years shows Allogene Therapeutics' Operating Expenses stood at $73.9 million in 2021, then soared by 30.4% to $96.4 million in 2022, then decreased by 11.71% to $85.1 million in 2023, then dropped by 28.94% to $60.5 million in 2024, then decreased by 25.77% to $44.9 million in 2025.
- Its last three reported values are $44.9 million in Q3 2025, $56.8 million for Q2 2025, and $65.2 million during Q1 2025.